Qiagen Amends Terms to Exiqon Acquisition Offer for Third Time | GenomeWeb

NEW YORK (GenomeWeb) – Qiagen took another step towards completing its DKK683 million ($105 million) acquisition of RNA analysis products developer Exiqon by reducing the acceptance threshold of the share capital and voting rights in Exiqon to around 89 percent from 90 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.